Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263637 | 0.91 | GAA (0.53) | ADORA3ADORA1ADORA2BGAAKMT2A | |
| SCHEMBL4271189 | 0.91 | ADORA1 (0.48) | ADORA3ADORA1ADORA2BGAAKMT2A | |
| SCHEMBL4263664 | 0.90 | S1PR1 (0.46) | ADORA3ADORA1ADORA2BGAAKMT2A | |
| SCHEMBL4259884 | 0.90 | KMT2A (0.46) | ADORA3ADORA1ADORA2BGAAKMT2A | |
| SCHEMBL4258743 | 0.90 | KMT2A (0.47) | ADORA3ADORA1ADORA2BGAAKMT2A | |
| SCHEMBL4273355 | 0.90 | KMT2A (0.49) | ADORA3ADORA1ADORA2BGAAKMT2A | |
| SCHEMBL4262513 | 0.89 | ADORA3 (0.48) | ADORA3ADORA1ADORA2BGAAKMT2A | |
| SCHEMBL4268162 | 0.89 | KMT2A (0.47) | ADORA3ADORA1ADORA2BGAAKMT2A | |
| SCHEMBL4260891 | 0.88 | KMT2A (0.46) | ADORA3ADORA1ADORA2BGAAKMT2A | |
| SCHEMBL4267115 | 0.88 | KMT2A (0.50) | ADORA3ADORA1ADORA2BGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048258-A1 | Amide Compound | DLAT, DGAT1, DGAT2 | ADORA3 591/4885ADORA1 570/4885ADORA2B 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.